Project Grant K23HL181383
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $175K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research led by Dr. James at the Trustees of Indiana University to investigate the role of aminopeptidase N (APN) in the development of pulmonary hypertension. The $249,000 award, effective August 1, 2025 through June 30, 2028, will enable Dr. James to gain additional training in research methodology and professional development, build a strong publication...
- This Project Grant award, titled "Alveolar Macrophage and Epithelial Cell Lipid Metabolism in Pulmonary Fibrosis", was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The $169,992 award supports a five-year research plan by Dr. Richard Watson, a clinical instructor at the University of California, Los Angeles (UCLA), to investigate the mechanisms of lipid metabolism in idiopathic pulmonary...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $163,790 to the University of Colorado-Denver over 5 years starting August 1, 2025. The grant will support the research training of Dr. Peter Moore, a physician-scientist, to advance the understanding of macrophage-produced coagulation factor XIII-A and its role in regulating the extracellular matrix and alveolar epithelial repair after acute lung injury....
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $190,998 Project Grant under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF). The 5-year grant will fund a research project titled "Understanding Pulmonary Fibrosis Through the Integration of Complex Occupational and Environmental Exposure Assessments (PF-OEM)." The project aims to use epidemiological tools to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a 2-year $189,000 research project led by an Assistant Professor at the University of Colorado to investigate the role of aldehyde dehydrogenase 2 (ALDH2) in the pathogenesis and resolution of fibroproliferative acute respiratory distress syndrome (FP-ARDS). The research aims to improve understanding of the mechanisms underlying pathologic pulmonary fibrogenesis...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- The National Heart Lung and Blood Institute, through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $164,160 Project Grant to the University of California, San Francisco (UCSF) to support a 5-year research plan led by Dr. Andrew Levine, M.D./Ph.D. The project seeks to understand the role of post-transcriptional RNA regulatory mechanisms in hematopoiesis, the process of blood cell formation. The research will be conducted under the mentorship of Dr. Davide...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $586,637 to the University of New Mexico (UNM) to conduct research into the mechanisms of immune dysregulation that contribute to the development of hypoxic pulmonary hypertension (PH). The research aims to identify how chronic hypoxia causes a decrease in regulatory T cells (Tregs) and promotes the development of self-reactive T helper 17 (Th17) cells that target...